drugset
Drugs / CARCCR9 T cells
last change Nov 2025 re-read 3 minutes ago

CARCCR9 T cells

Cell therapy targets CCR9

Developed for
T-cell acute lymphoblastic leukemia · T-lymphoblastic lymphoma
Investigated by
Great Ormond Street Hospital Charity · Medical Research Council · University College, London

Trials 1

today NCT07300683 · Ph 1
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07300683 Nov 2025 → Dec 2027 expected T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma University College, London Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CARCCR9 T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300683 ↗
Modality Cell therapy “Anti-CCR9 CAR T cells” NCT07300683 ↗
Route Intravenous “Patients will receive autologous anti-CCR9 CAR T cells intravenously.” NCT07300683 ↗
Target CCR9 “Targeting CCR9” NCT07300683 ↗